CRISPR Base Editing Advances Toward Rare Disease Therapies

WHY IT MATTERS

Base editing may be safer than traditional CRISPR, expanding gene therapy to more rare diseases.

Beam Therapeutics reported positive interim data from base editing for sickle cell disease, showing efficient editing without double-strand DNA breaks.

Related conditions